))
A Discussion with Gil Aharon of Rosalind Advisors: Biotech Investing, Verona Pharma & Delcath Systems
Manage episode 337249289 series 3380517
Inhalt bereitgestellt von Encode Ideas, L.P., Encode Ideas, and L.P.. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von Encode Ideas, L.P., Encode Ideas, and L.P. oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.
An interview with Gil Aharon of Rosalind Advisors, where we discuss his perspective on the macro biotech market. Having run a dedicated life science fund for >10 years, Gil puts today's difficult biotech market into historical context and offers his opinion on why investors should be optimistic for the future. During the interview, we also discuss two of Gil's favorite smaller health care names, Verona Pharma and Delcath Systems.
Companies discussed during the podcast;
- Verona Pharma plc (Nasdaq: VRNA)
- Delcath Systems, Inc (Nasdaq: DCTH)
- Immunogen Inc (Nasdaq: IMGN)
Gil Aharon, who is a director of Delcath Systems, Inc. (“Delcath”) appeared on this episode of the podcast. Listeners are urged to review Delcath’s SEC filings and cautioned not to place undue reliance on any forward-looking statements. Delcath undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.
7 Episoden
Teilen
